Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

"These data demonstrate the safety of MYDICAR, and the improvements in cardiac function and overall condition observed in some patients further validate our target and approach," said Krisztina M. Zsebo, Ph.D., Chief Executive Officer of Celladon. "Given these early encouraging results, we are excited to have been given clearance to move into phase 2 of our study to continue to evaluate the ability of MYDICAR to improve heart function in more patients."

CUPID, which is funded by Celladon, is a Phase 1/2 trial. The Phase 1 portion reported today is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. CUPID is expected to enroll 46 patients with advanced heart failure at 15 U.S. medical centers.

Study Results

Data from the Phase I in advanced heart failure was presented, and demonstrated that MYDICAR had an acceptable safety profile in these first nine patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months across a number of parameters important in assessing heart failure status were observed, including symptomatic (5 patients), functional (4 patients), biomarker (2 patients) and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters.

The data are consistent with safety established for other rAAV vectors, which has been demonstrated in cl
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... 30, 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 , ... , 51% Non-GAAP Net Sales , $278.8 Million , ... $1.54 , $1.12 , 37% Non-GAAP ... , 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 ...
(Date:7/24/2014)... Texas , July 24, 2014  To ... the cardiovascular market that could impact patient care ... Spring 2014 CV Watch , "Innovations in Cardiovascular ... provides hospitals with guidance and details on promising ... patient needs and understand how these options impact ...
(Date:7/24/2014)... 2014  Blueprint Medicines (Blueprint), a leader in discovering ... today announced the appointment of Jeffrey Albers ... from Algeta ASA, where he served on the executive ... by Bayer. Mr. Albers succeeds Alexis Borisy , ... Third Rock Ventures, who will remain an active member ...
Breaking Medicine Technology:Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2
(Date:7/24/2014)... with strong reading skills may be on a fast track ... Kids with above average reading skills may have higher intelligence ... The study included 1,890 identical twins from Great Britain who ... 7, 9, 10, 12 and 16. Because each pair of ... between them had to be due to factors they didn,t ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 At the ... Annual Conference & Expo on July 17 – 20, ... national awards for individuals, organizations, and chapter recipients. ... including Dr. Michael Anderson, Vice President and Chief Medical ... Experience Officer for Cleveland Clinic; and Cleveland Mayor Frank ...
(Date:7/24/2014)... 2014 Jason Feruggia is regularly featured ... has been called the greatest strength and conditioning coach ... successful career producing his own fitness information products. Bedros ... franchise in the country and also considered the industry’s ... an old friend and colleague of Feruggia’s and recently ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... that shows some fibromyalgia patients may benefit from ... Advanced Parathyroid Surgery in Beverly Hills today commented ... , “Hyperparathyroidism is often misdiagnosed because its symptoms ... Dr. Larian explained. “Those who have been diagnosed ...
(Date:7/24/2014)... 24, 2014 6 Minutes to Skinny ... metabolism into high gear with only a few minutes ... one’s diet or lifestyle. This has caught the attention ... “Our 6 Minutes to Skinny review shows ... time to understand exactly how your body responds to ...
Breaking Medicine News(10 mins):Health News:Young Readers, Tomorrow's Leaders? 2Health News:CMSA Presents 2014 National Case Management Awards at Annual Conference & Expo 2Health News:CMSA Presents 2014 National Case Management Awards at Annual Conference & Expo 3Health News:CMSA Presents 2014 National Case Management Awards at Annual Conference & Expo 4Health News:New Video Release: Jason Feruggia’s Interview with Personal Trainer Marketing Expert Bedros Keuilian 2Health News:New Video Release: Jason Feruggia’s Interview with Personal Trainer Marketing Expert Bedros Keuilian 3Health News:Is Hyperparathyroidism Misdiagnosed as Fibromyalgia? 2Health News:Is Hyperparathyroidism Misdiagnosed as Fibromyalgia? 3Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 2Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 3
... used as a bioterrorist tool eludes being killed by ... of Iowa// researchers report in the December issue of ... Francisella tularensis, is found naturally in the Northern Hemisphere ... with infected rabbits or ingesting contaminated food, water or ...
... Researchers at the University of Texas M. D. Anderson Cancer ... over the span of 40 years reduced the tumor growth ... of chemotherapy. ,The Journal of the National Cancer ... and the drug cromolyn is three times more effective than ...
... Yong, today urged Australians to spare a thought this week ... ,'This time of year for most people means joyful gatherings ... isolation and despair,' Dr Yong said. ,'The social ... year can cause depression for those who are socially isolated. ...
... Vietnam went on high alert Wednesday following the first confirmed ... even as thousands of poultry were slaughtered in the// Mekong ... large numbers in southern Ca Mau and Bac Lieu provinces, ... positive for the H5N1 strain of avian influenza. ...
... doing physical exercises and keeping active to stay fit, old ... their brains remain agile, if they just indulge// in brain ... as they advance in age, researchers said. ,Previous ... crossword puzzles and mind games. The study led by Sherry ...
... get shorter in late autumn and often does not disappear ... sufferers long periods of feeling down, but also is accompanied ... and a state of anxiety. Experts say one of the ... ,The problem occurs because when the days get shorter ...
Cached Medicine News:Health News:Clues Found On How Deadly Bacterium Gains Foothold 2Health News:Clues Found On How Deadly Bacterium Gains Foothold 3Health News:Anti Allergy Drugs Reduce Tumor Growth 2Health News:Anti Allergy Drugs Reduce Tumor Growth 3Health News:Light Therapy Fights Depression With Sun Substitute 2
... of the LX2000 Series and optimize ... compromising testing quality.Plus, when you equip ... you get advanced features that you ... analyzer, including closed tube sampling and ...
Help restore pelvic muscle function with the Prometheus Pathway CTS 2000 evaluation and training system....
... By using multi-channel catheters ... and/or proximal esophagus, the catheter-based pH test ... from a pharmaceutical agent) in the stomach ... relation to ENT or pulmonary symptoms. Ability ...
... of digital imaging technology, pathology specimen ... formats, allowing for easier manipulation, analysis, ... digital pathology imaging is analogous to ... and which is continuing to occur ...
Medicine Products: